



EmboMedics closes in Series A financing round, is awarded patent and gets new chairman

EmboMedics closes in on Series A Finance Round

MINNEAPOLIS, MN, USA, February 4, 2014 /EINPresswire.com/ -- EmboMedics announced today that Mr. Gerald Van Eeckhout has agreed to join EmboMedics as Chairman of the Board. Mr. Van Eeckhout is presently Chairman of Evergreen Enterprises LLC, and previously served as CEO of ConferTech International (NASDAQ) from 1982 to 1990 and CEO of ACT Teleconferencing (NASDAQ) from 1990 to 2003, when he retired. His management career includes seven years as Controller, Vice President, Chief Financial and Administrative Officer of Medtronic Inc (NYSE), five years as Chief Financial and Planning Officer of The Pillsbury Co. International Division, and eight years as a CPA with Touche Ross and Co, all in Minneapolis, Minnesota. Jerry was recently the Director and Chairman of Medafor's (sold to BARD) finance committee. He received a BS in Accounting from the University of North Dakota and is a 1976 graduate of the Stanford Business School Executive Program. He has served as an outside director of several public and private companies in the US and China in the telecommunications, food, medical technology, and non-profit sectors. He is a former National Director of the American Electronics Association, a past President of the University of North Dakota Foundation and currently a Trustee of the University of North Dakota Entrepreneurial Studies Foundation and a Board member of the Rocky Mountain World Trade Association. He was named the 2001 Ernst and Young "Entrepreneur of the Year" for the Rocky Mountain region. He has served as a Professor of Accounting, Finance, Marketing, and International Management at the University of Minnesota, the University of Denver and the University of Shanghai.

"We welcome Jerry as a valuable part of our team and will surely rely on his tremendous experience to guide us in the right path", said Omid Souresrafil CEO of EmboMedics. This coincides with the closing of Series A financing round and the award of our patent by USPTO. We have been very fortunate to have closed out financing, round and have now the means, tools and the people to continue our work to make this life saving technology available to the general population", said Souresrafil.

Omid Souresrafil
EmboMedics
6128172349
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/188855755>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.